---
title: "Exozymes FY26 Q2 net loss widens 22% to $2.88 million; revenue remains no revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295837658.md"
description: "Exozymes reported a widened net loss of $2.88 million for Q2 FY26, with no revenue generated. The six-month net loss reached $5.25 million, driven by an 85.7% surge in R&D costs to $2.56 million and rising operating expenses. Despite cash reserves increasing to $5.65 million from recent offerings, management expressed substantial doubt about the company's ability to continue as a going concern due to insufficient working capital."
datetime: "2026-08-13T19:50:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295837658.md)
  - [en](https://longbridge.com/en/news/295837658.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295837658.md)
generator: "portal-rs"
---

# Exozymes FY26 Q2 net loss widens 22% to $2.88 million; revenue remains no revenue

-   Exozymes posted a net loss of USD 5.25 million for the six months ended June 30, 2026, widening 24.5% year over year. \* Operating loss widened 18.7% to USD 5.34 million, as operating costs rose 18.7% to USD 5.34 million. \* Research and development costs jumped 85.7% to USD 2.56 million, due to higher compensation and lab expenses plus reduced grant funding. \* Cash and cash equivalents climbed 86% to USD 5.65 million following June 2026 offerings with net proceeds of USD 5.86 million. \* Management flagged substantial doubt about going concern, citing working capital of USD 4.55 million as insufficient for 12 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037725), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EXOZ.US](https://longbridge.com/en/quote/EXOZ.US.md)

## Related News & Research

- [EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization](https://longbridge.com/en/news/296532185.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)
- [Masoval to present Q2 2026 results in investor briefing](https://longbridge.com/en/news/296509895.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**